<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:chebi fb="0" ids="35457">Angiotensin-converting enzyme inhibitors</z:chebi> have been shown to protect against <z:hpo ids='HP_0001297'>stroke</z:hpo> in hypertensive rats and to improve neurological outcome after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in normotensive rats </plain></SENT>
<SENT sid="1" pm="."><plain>The present study was designated to test the hypothesis that blockade of brain AT(1) receptors improves the recovery from focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and reduces expression of AP-1 transcription factors c-Fos and c-Jun, which have been associated with programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> and <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Experiments were carried out in normotensive male Wistar rats </plain></SENT>
<SENT sid="3" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> lasting for 90 minutes and followed by reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>The selective AT(1) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="5959">irbesartan</z:chebi> was infused intracerebroventricularly over a 5-day period before the induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> at a dose that inhibited brain but not vascular AT(1) receptors </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-four hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, neurological outcome was evaluated and expression of c-Fos and c-Jun proteins in the brain was studied immunocytochemically </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> resulted in a strong induction of c-Fos and c-Jun proteins in the cortex, which positively correlated with the degree of neurological deficits </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment of rats with <z:chebi fb="0" ids="5959">irbesartan</z:chebi> significantly improved neurological outcome of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> when compared with the vehicle-treated group and markedly reduced the expression of c-Fos and c-Jun proteins in the cortex on the ligated side of the brain </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="5959">Irbesartan</z:chebi> pretreatment completely abolished the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced c-Fos expression in the hippocampus </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The present study shows a relationship between c-Fos and c-Jun expression and neurological outcome after focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Our data indicate that long-term blockade of central AT(1) receptors improves the recovery from <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> and reduces the expression of c-Fos and c-Jun proteins in the brain </plain></SENT>
<SENT sid="11" pm="."><plain>Pretreatment with an AT(1) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> has beneficial effects after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>